Petar Seferović works in Heart Failure & Transplant affiliated with University of Belgrade.
Petar Seferović is a professor of internal medicine and cardiology at the University of Belgrade Faculty of Medicine. He is an academician at the Serbian Academy of Sciences and Arts and president of the Heart Failure Society of Serbia. He previously served as president of the Heart Failure Association of the European Society of Cardiology from 2018 to 2020.
428 pubs · 60,909 cites · h-index 94
MD
University of Belgrade School of Medicine
1976
PhD
University of Belgrade School of Medicine
1990
Professor of Internal Medicine and Cardiology
University of Belgrade Faculty of Medicine · 2000 - Present
Academician
Serbian Academy of Sciences and Arts · 2018 - Present
President
Heart Failure Society of Serbia · 2011 - Present
Vice-President
European Society of Cardiology · 2020 - 2022
President
Heart Failure Association of the European Society of Cardiology · 2018 - 2020
Offers first structured guidance on arrhythmia management in myocarditis; extends mechanistic insights on inflammation and fibrosis into clinical protocols.
Supports precipitant assessment in acute HF care; extends global synthesis but leaves open prospective outcome trials.
Professor of medicine, Baylor Scott & White · Baylor Scott & White Research Institute
These data suggest that you can simultaneously control potassium and optimize RAASi therapy, and perhaps in the long run, it would improve clinical outcomes, but we did not have enough outcomes to make any definitive conclusion in that respect.
European Heart JournalButler et al.
Director of Cardiology, Hannover Medical School · Medizinische Hochschule Hannover
The data from our latest study suggest that a subsequent pregnancy in PPCM patients with a justifiable risk seems possible not only when heart function has recovered, but also when it is only slightly restricted.
European Heart JournalSliwa et al.
LFT abnormalities may aid prognostication in acute HF; hypothesis-generating for whether decongestion reverses injury and improves outcomes.
This perspective challenges the traditional LVEF-based classification of heart failure, advocating for a more nuanced understanding of HF as a continuous spectrum of phenotypes.
Survey reveals improvements in guideline-directed medical therapies and device use in heart failure patients across Central/Eastern Europe.
Scientific statement outlines SGLT2 inhibitors' role in treating heart failure and type 2 diabetes, suggesting improved outcomes.
This review reveals the diagnostic potential of biomarkers in right ventricular dysfunction, highlighting challenges in accuracy.
This clinical consensus statement provides a systematic strategy for risk assessment and personalized cardiac screening of family members of patients with dilated cardiomyopathy.
This narrative review analyzes the definition and clinical implications of hypertensive acute heart failure, suggesting an alternative descriptor for better treatment outcomes.
Petar M Seferović, Marija M Polovina; Mapping the modern heart failure epidemic: Growing burden, root causes and widening inequalities, European Heart Jour
This scientific statement outlines strategies to improve the translation of basic research into effective heart failure therapies by bridging the gap between bench and bedside.
This survey highlights significant gaps and socioeconomic disparities in the availability of heart failure management resources and advanced therapies across ESC member countries.
Provides updated European HF incidence, prevalence, and mortality benchmarks; extends prior atlases with 2021–2023 data across 43 countries.
Supports continued COVID-19 vaccination; confirms lower myocarditis risk and severity versus infection.
Limits vasodilator role to symptom relief in acute HF; reinforces 2021 ESC downgrades and prioritizes phenotype-targeted trials.
OBJECTIVE: The aim of this study was to evaluate the level of agreement among international experts on the World Scleroderma Foundation/Heart Failure Association consensus-based definition of systemic sclerosis-associated primary heart involvement (SSc-pHI) and on the guidance for its screening, diagnosis, and follow-up assessment, including feasibility and applicability assessments. METHODS: ). The weblink to the survey was shared with 1199 participants worldwide. A high level of agreement was defined by an average score over 7/10. RESULTS: In total, 161 external experts completed the survey. Most of them were rheumatologists (80.7%), working in Europe (81.4%), and had > 10 years of clinical experience in managing SSc patients (59%). Overall agreement among external experts was high (mean 8.27, SD 1.86). The highest scores regarded items emphasizing the involvement of a multidisciplinary team, personalization of patient management, and initial evaluation techniques. A lower level of agreement was obtained in questions related to cardiac magnetic resonance imaging and endomyocardial biopsy. No factors associated with low level of agreement and feasibility/applicability were identified. CONCLUSION: The consensus-based definition and guidance on screening, diagnosis, and follow-up assessment of SSc-pHI provides a basis for application by the wider community. A lower level of agreement on the use of advanced or more invasive diagnostic techniques likely reflects regional differences in access and the need for more evidence on its use. This emphasizes the importance of involving a multidisciplinary team.
